Q2 sales grew 12.5% year-over-year, driven by strong TAVR, TMTT, and surgical performance. Full-year 2026 sales and EPS guidance were raised, with robust operating margins and continued investment in innovation. TAVR and TMTT segments saw significant adoption and expanded indications.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.